News

SanAir Technologies Laboratory Combines with Centek Laboratories

Expands Lab Testing Capabilities into Volatile Organic Compound (VOC) Air and Soil Gas Analysis

RICHMOND, Va., SanAir Technologies Laboratory, Inc. (SanAir) today announced its merger with Syracuse, NY-based Centek Laboratories, LLC (Centek), expanding its testing capabilities into VOCs using summa cannister and/or thermal desorption tubes technology (EPA Method TO-15 and TO-17) and analyzation of samples by GC/MS coupled with cryo-focusing or thermal desorption technology.

“Like SanAir, Centek is in the environmental laboratory analysis business but with additional capabilities not currently covered by our lab,” said SanAir President Sean P. McGlynn. “Centek has been a leader in vapor intrusion technology since they opened their doors in 2003, when they helped New York State’s Department of Health and its Department of Environmental Conservation change how samples were collected and tested, improving the technology to save money and increase detection limits in the ppb (part per billion) and ppt (part per trillion) detection range. They have brought that innovative, client-focused spirit to LEED®, WELL, IgCC Certification System; Biogas, Industrial Hygiene and Product Testing. We are excited to have Centek under the SanAir umbrella.”

The combined laboratories represent a total of 70 employees in Virginia, Ohio and New York.

Centek has been working in green and sustainable technology through indoor air quality (IAQ) testing since 2009 in conjunction with the U.S. Green Building Counsel (USGBC). Current testing programs include: LEED® IEQ Credit 3.2 2009 for New Construction and Major Renovations; LEED V4; LEED 4.1; WELL; and IgCC. Centek has been doing this testing throughout the United States, Canada and Mexico and is starting to open doors overseas.

Centek also has been testing BioGas reclamation systems in landfills and wastewater treatment plants (WWTP) throughout North America. The lab identifies a complete gas profile and determines the proper treatment processes needed to meet even the most stringent biogas specifications for use as a fuel.

“We are excited about the opportunities presented by our merger with SanAir,” said Russell Pellegrino, Centek’s Technical Director. “Our companies are similarly entrepreneurial but also grounded in our foundational principles of scientific accuracy and reliability in testing.

SanAir’s resources will help Centek continue to innovate and bring cost and time-efficient sampling solutions to our clients.”

The combination of the two laboratories caps a year of expansion for SanAir that includes moving into a new headquarters location in Greater Richmond (North Chesterfield) at the former Virginia Department of Emergency Management location, and the first fully operational and accredited year of industrial hemp and medical marijuana testing for the Company’s wholly-owned subsidiary, Sativa Testing Laboratories.

Read more here.

Recent News

03/19/2026

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a new genetic testing program with Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a commercial-stage biopharmaceutical company focused on bringing life-changing therapeutics to people living with rare diseases. The Niemann-Pick Disease type C (NPC) Sponsored Genetic Testing

03/18/2026

Phlow Corp. Appoints Dawn Von Rohr as Chief Operating Officer to Advance Domestic Pharmaceutical Manufacturing

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that Dawn Von Rohr has been appointed Chief Operating Officer (COO). Von Rohr will oversee Phlow’s operations, manufacturing execution, and strategic growth initiatives as the company continues expanding its advanced pharmaceutical development and manufacturing infrastructure in the United States to

03/17/2026

W&M Undergrads expand the chemical toolbox for cancer drugs

Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from unwanted side effects and limited efficacy. In a recent Bioconjugate Chemistry publication, William & Mary researchers designed an antibody-drug conjugate (ADC) with the potential to improve the potency and decrease the cost of currently approved cancer drugs. Like